Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)
Primary Purpose
Type 2 Diabetes
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
MK-8655
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring Type 2 Diabetes
Eligibility Criteria
Inclusion Criteria:
- Male or female of non-child bearing potential
- Body Mass Index ≤40 kg/m^2
- Diagnosis of Type 2 Diabetes (T2DM) and is either drug naive or is being treated with metformin only
- In good health except for T2DM
- Willing to follow a standard diet
- Nonsmoker and/or no use of nicotine or nicotine-containing products for 6 months
Exclusion Criteria:
- Mentally or legally incapacitated
- History of stroke, chronic seizures, or major neurological disorder
- History of clinically significant endocrine (except T2DM), gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases
- History of neoplastic or myeloproliferative diseases
- Has clinical unstable or rapidly progressing diabetic retinopathy, neuropathy, and/or frequent nausea, bloating or vomiting, severe gastroesophageal reflux or early satiety
- Has a history of Type 1 Diabetes and/or history of ketoacidosis
- Use of any lipid-lowering therapies in the past 3 months
- Non-permitted medication for a co-morbid condition
- Excessive alcohol or caffeine use
- Participation in another investigational study within 4 weeks prior to this study
- A history of significant multiple and/or severe allergies or anaphylactic reactions
- Regular user of any illicit drugs or history of alcohol abuse within 6 months
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
MK-8655 80 mg/MK-8655 320 mg
Placebo
Arm Description
Participants received a single dose of MK-8655, 80 mg on Day 1 and then MK-8655 320 mg, once daily, starting on Day 3 for 14 consecutive days.
Participants received a single dose of placebo to MK-8655, 80 mg on Day 1 and then placebo to MK-8655 320 mg, once daily, starting on Day 3 for 14 consecutive days.
Outcomes
Primary Outcome Measures
Number of Participants With One or More Adverse Events
An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Number of Participants Discontinuing Study Drug Due to an Adverse Event
An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Fasting Plasma Glucose (FPG)
Blood for fasting plasma glucose (central laboratory) was obtained after at least 10 hours overnight fast.
Secondary Outcome Measures
True Geometric Mean Plasma Concentrations of MK-8655 After Single and Multiple Drug Doses at 24 Hours Post Dose (C24)
C24hr was log transformed and analyzed based on a linear mixed effects model containing fixed effects for treatment, day and treatment by day interaction and a random effect for the participant.
24-Hour Weighted Mean Glucose (WMG)
The WMG provides an integrated assessment of the glycemic exposure over the 24-hour period. To reduce variability of the baseline (before any study drug administration) WMG, participants were domiciled in the test facility at least 36 hours prior to Day 1, where standard meals were provided, and physical activity was monitored. The WMG was derived from multiple glucose values collected during both fasting and post-meal periods. The sample scheme for the 18 point glucose measurements used in this study had many samples taken in the very early morning hours, as well as the first three hours after meals. WMG was calculated as the area under the curve (AUC) of the glucose concentrations divided by the duration of time of samples collected.
Change From Baseline at 2 Hours Oral Glucose Tolerance Test
Plasma glucose excursion was assessed during an oral glucose tolerance test (oGTT) following a single dose administration of MK-8655 in participants with T2DM.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01640873
Brief Title
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)
Official Title
A Randomized Double-Blind Placebo-Controlled Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Subjects With Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
April 2018
Overall Recruitment Status
Completed
Study Start Date
September 19, 2012 (Actual)
Primary Completion Date
December 20, 2012 (Actual)
Study Completion Date
December 20, 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Merck Sharp & Dohme LLC
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study will assess the initial safety, tolerability, pharmacokinetics, and pharmacodynamics of MK-8655, after single and multiple daily oral administrations to participants with Type 2 Diabetes (T2DM). The study will assess the reduction in fasting plasma glucose concentrations from baseline after multiple daily administrations of MK-8655.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Type 2 Diabetes
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
33 (Actual)
8. Arms, Groups, and Interventions
Arm Title
MK-8655 80 mg/MK-8655 320 mg
Arm Type
Experimental
Arm Description
Participants received a single dose of MK-8655, 80 mg on Day 1 and then MK-8655 320 mg, once daily, starting on Day 3 for 14 consecutive days.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants received a single dose of placebo to MK-8655, 80 mg on Day 1 and then placebo to MK-8655 320 mg, once daily, starting on Day 3 for 14 consecutive days.
Intervention Type
Drug
Intervention Name(s)
MK-8655
Intervention Description
Participants will receive MK-8655 as a single dose on Day 1. Participants will receive MK-8655, once a day (q.d.), for 14 consecutive days (Day 3 through Day 16). MK-8655 doses may be adjusted downward based on the results of ongoing studies.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Participants will receive Placebo as a single dose on Day 1. Participants will receive Placebo, q.d., for 14 consecutive days (Day 3 through Day 16).
Primary Outcome Measure Information:
Title
Number of Participants With One or More Adverse Events
Description
An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time Frame
Up to 14 days after the last dose of study drug (Up to 31 days)
Title
Number of Participants Discontinuing Study Drug Due to an Adverse Event
Description
An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time Frame
Up to 17 days
Title
Fasting Plasma Glucose (FPG)
Description
Blood for fasting plasma glucose (central laboratory) was obtained after at least 10 hours overnight fast.
Time Frame
Day 16 (Predose)
Secondary Outcome Measure Information:
Title
True Geometric Mean Plasma Concentrations of MK-8655 After Single and Multiple Drug Doses at 24 Hours Post Dose (C24)
Description
C24hr was log transformed and analyzed based on a linear mixed effects model containing fixed effects for treatment, day and treatment by day interaction and a random effect for the participant.
Time Frame
24 hours post dose on Days 1, 7, and 14
Title
24-Hour Weighted Mean Glucose (WMG)
Description
The WMG provides an integrated assessment of the glycemic exposure over the 24-hour period. To reduce variability of the baseline (before any study drug administration) WMG, participants were domiciled in the test facility at least 36 hours prior to Day 1, where standard meals were provided, and physical activity was monitored. The WMG was derived from multiple glucose values collected during both fasting and post-meal periods. The sample scheme for the 18 point glucose measurements used in this study had many samples taken in the very early morning hours, as well as the first three hours after meals. WMG was calculated as the area under the curve (AUC) of the glucose concentrations divided by the duration of time of samples collected.
Time Frame
Day 15: Predose, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 18, 21, 23 hours post-dose.
Title
Change From Baseline at 2 Hours Oral Glucose Tolerance Test
Description
Plasma glucose excursion was assessed during an oral glucose tolerance test (oGTT) following a single dose administration of MK-8655 in participants with T2DM.
Time Frame
Baseline and 2 hours after dosing on Days 1, 3, and 16
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female of non-child bearing potential
Body Mass Index ≤40 kg/m^2
Diagnosis of Type 2 Diabetes (T2DM) and is either drug naive or is being treated with metformin only
In good health except for T2DM
Willing to follow a standard diet
Nonsmoker and/or no use of nicotine or nicotine-containing products for 6 months
Exclusion Criteria:
Mentally or legally incapacitated
History of stroke, chronic seizures, or major neurological disorder
History of clinically significant endocrine (except T2DM), gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases
History of neoplastic or myeloproliferative diseases
Has clinical unstable or rapidly progressing diabetic retinopathy, neuropathy, and/or frequent nausea, bloating or vomiting, severe gastroesophageal reflux or early satiety
Has a history of Type 1 Diabetes and/or history of ketoacidosis
Use of any lipid-lowering therapies in the past 3 months
Non-permitted medication for a co-morbid condition
Excessive alcohol or caffeine use
Participation in another investigational study within 4 weeks prior to this study
A history of significant multiple and/or severe allergies or anaphylactic reactions
Regular user of any illicit drugs or history of alcohol abuse within 6 months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Director
Organizational Affiliation
Merck Sharp & Dohme LLC
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)
We'll reach out to this number within 24 hrs